Research Corporation Technologies — 2019 Investments
1 investments dated 2019 · listed companies and verified rows first · show all
Esperancepharmaesperancepharma.comJun 2019✓ verified
Esperance develops targeted oncology therapeutics designed to selectively kill cancer cells, including chemotherapy-resistant cells, via a proprietary Cationic Lytic Peptide (CLYP) platform, membrane-disrupting peptides, and antibody drug conjugates.
BiotechHealthtechHouston, US
Hector Alila(Executive Officer, Director)Ross Barrett(Director)Peter Hoang(Director)Sonia Deggs(Executive Officer)Carola Leuschner(Executive Officer)
BoardJoseph Lovett(Director)
Co-investorsLouisiana Funds
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.